Mostrar el registro sencillo del ítem
dc.contributor.author | Verweij, Paul E | |
dc.contributor.author | Arendrup, Maiken C | |
dc.contributor.author | Alastruey-Izquierdo, Ana | |
dc.contributor.author | Gold, Jeremy A W | |
dc.contributor.author | Lockhart, Shawn R | |
dc.contributor.author | Chiller, Tom | |
dc.contributor.author | White, P Lewis | |
dc.date.accessioned | 2023-05-08T07:55:35Z | |
dc.date.available | 2023-05-08T07:55:35Z | |
dc.date.issued | 2022-12 | |
dc.identifier.citation | Drug Resist Updat. 2022 Dec;65:100885. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16006 | |
dc.description.abstract | Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Aspergillus fumigatus | es_ES |
dc.subject | DHODH inhibitor | es_ES |
dc.subject | One Health | es_ES |
dc.subject | Olorofim | es_ES |
dc.subject | Triazole resistance | es_ES |
dc.subject.mesh | Antifungal Agents | es_ES |
dc.subject.mesh | Fungicides, Industrial | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Drug Resistance, Fungal | es_ES |
dc.subject.mesh | Azoles | es_ES |
dc.subject.mesh | Aspergillus fumigatus | es_ES |
dc.subject.mesh | Agriculture | es_ES |
dc.subject.mesh | Microbial Sensitivity Tests | es_ES |
dc.title | Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens? | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 36283187 | es_ES |
dc.format.volume | 65 | es_ES |
dc.format.page | 100885 | es_ES |
dc.identifier.doi | 10.1016/j.drup.2022.100885 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1532-2084 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.drup.2022 | es_ES |
dc.identifier.journal | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |